Similar articles

• Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea.

  Taylor SN, Marrazzo J, Batteiger BE, Hook EW 3rd, Seña AC, Long J, Wierzbicki MR, Kwak H, Johnson SM, Lawrence K, Mueller J. Taylor SN, et al. N Engl J Med. 2018 Nov 8;379(19):1835-1845. doi: 10.1056/NEJMoa1706988. N Engl J Med. 2018. PMID: 30403954 Clinical Trial.
• New treatment options for Neisseria gonorrhoeae in the era of emerging antimicrobial resistance.

  Lewis DA. Lewis DA. Sex Health. 2019 Sep;16(5):449-456. doi: 10.1071/SH19034. Sex Health. 2019. PMID: 31292063 Review.
• Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of Neisseria gonorrheae, Including Multi-Drug-Resistant Isolates.

  Bradford PA, Miller AA, O'Donnell J, Mueller JP. Bradford PA, et al. ACS Infect Dis. 2020 Jun 12;6(6):1332-1345. doi: 10.1021/acsinfecdis.0c00021. Epub 2020 May 12. ACS Infect Dis. 2020. PMID: 32329999
• Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.

  Basarab GS, Kern GH, McNulty J, Mueller JP, Lawrence K, Vishwanathan K, Alm RA, Barvian K, Doig P, Galullo V, Gardner H, Gowravaram M, Huband M, Kimzey A, Morningstar M, Kutschke A, Lahiri SD, Perros M, Singh R, Schuck VJ, Tommasi R, Walkup G, Newman JV. Basarab GS, et al. Sci Rep. 2015 Jul 14;5:11827. doi: 10.1038/srep11827. Sci Rep. 2015. PMID: 26168713 Free PMC article. Clinical Trial.
• New treatment options for infections caused by increasingly antimicrobial-resistant Neisseria gonorrhoeae.

  Lee H, Lee K, Chong Y. Lee H, et al. Expert Rev Anti Infect Ther. 2016;14(2):243-56. doi: 10.1586/14787210.2016.1134315. Expert Rev Anti Infect Ther. 2016. PMID: 26690658 Review.